Answers are grounded in this paper and cite their sources.
Inhibition of GALNT7 decreases cell proliferation and invasiveness in non-small cell lung cancer, suggesting therapeutic potential.
Objective Polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7) is a glycopeptide transferase which is closely involved in the development and progression of cancer. This study aimed to investigate the effects of GALNT7 inhibition on non-small cell lung cancer (NSCLC) cell proliferation, apoptosis and invasiveness and to determine whether these effects are mediated by the protein kinase B (AKT) pathway. Methods Negative control small interfering RNA (siRNA) (si-NC) and siRNA targeting GALNT7 (si-GALNT7) were transfected into A549 and NCI-H1650 cells. Afterwards, the AKT activator ‘740 Y-P’ was added to treat the cells with or without siRNA transfection. Results Cell proliferation was reduced after si-GALNT7 transfection compared with si-NC transfection at 24 hours, 48 hours and 72 hours in A549 cells, and at 48 hours and 72 hours in NCI-H1650 cells. Furthermore, the cell apoptosis rate was increased, but the cell invasive number was decreased after si-GALNT7 transfection compared with si-NC transfection in A549 cells and NCI-H1650 cells. Phosphorylated (p)-AKT/AKT expression was lower after si-GALNT7 transfection compared with si-NC transfection in A549 cells and NCI-H1650 cells. Worth noting, the effects of si-GALNT7 transfection on the above-mentioned cell proliferation, apoptosis and invasiveness were repressed by the addition of 740 Y-P in A549 cells and NCI-H1650 cells. Conclusion GALNT7 inhibition suppresses NSCLC cell proliferation and invasiveness while increasing apoptosis through inactivation of the AKT pathway.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: